CHMP issues positive recommendation for approval of lecanemab in the EU
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...
BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats
BridgeBio Pharma’s acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if ...
Innate Pharma S.A. (NASDAQ:IPHA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Hello and thank you for standing by. My name is Regina and will ...
It News Online9h
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion ...
AirBnB and 5 More High-Quality Stocks for a Market Rally
All 11 sectors are in the green for the year. The optimism comes as the economy is likely to continue to grow because the ...
Merck to buy rights to Chinese cancer drug for up to $3.3B
Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...
Business Insider21h
AstraZeneca: Overcoming Short-term Challenges with Robust Long-term Potential
Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination of ...